Current results in the clinical therapy of schistosomiasis mansoni.
D000818:Animals; D004159:Diphenylamine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006826:Hycanthone / Q000009:adverse effects / Q000627:therapeutic use; D017879:Isothiocyanates; D009560:Niridazole / Q000009:adverse effects / Q000627:therapeutic use; D010073:Oxamniquine / Q000009:adverse effects / Q000627:therapeutic use; D011223:Praziquantel / Q000009:adverse effects / Q000627:therapeutic use; D012550:Schistosoma mansoni; D012552:Schistosomiasis / Q000188:drug therapy*; D012556:Schistosomicides / Q000009:adverse effects / Q000627:therapeutic use*; D013861:Thiocyanates / Q000009:adverse effects / Q000627:therapeutic use
D017879:Isothiocyanates; D012556:Schistosomicides; D013861:Thiocyanates; D010073:Oxamniquine; D006826:Hycanthone; D011223:Praziquantel; D004159:Diphenylamine; D009560:Niridazole; C012391:amoscanate